Scholarlink

Purpose of the Review <p>This review aims to examine the clinical relevance of cardio-kidney-metabolic syndrome (CKMS) in oncology, highlighting its role as both a preexisting comorbidity and a consequence of cancer treatment. It aims to integrating CKMS staging into personalized cancer care.</p> Recent Findings <p>CKMS is a progressive syndrome marked by dysfunction across cardiovascular, renal, and metabolic systems. Cancer therapies—particularly hormonal agents, immune checkpoint inhibitors, and chemotherapeutics—can accelerate or reveal underlying CKMS through inflammatory and metabolic pathways. Early risk stratification based on CKMS stage enables more effective monitoring, referral, and therapeutic strategies. A stage-based, multidisciplinary approach tailored to cancer type and comorbidity burden is essential for optimizing outcomes.</p> Summary <p>With rising multimorbidity among cancer patients, recognizing and addressing CKMS is increasingly critical. Routine CKMS assessment in oncology offers a pathway for earlier intervention and potentially altering its course. A comprehensive, individualized care model based on CKS stage is necessary to mitigate CKMS-related complications and deliver high-quality, integrated cancer care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Tackling the Cardio-Kidney-Metabolic Burden in Cancer

  • 期刊论文

  • 发表日期：

    2025年9月15日

查看全文
  • Tarek Nahle,
  • Viraj Shah,
  • Harikrishnan Hyma Kunhiraman,
  • Omar M. Makram,
  • Ola Ahmed,
  • Sandeep Yerraguntla,
  • Gaurav Gopu,
  • Jenny Vy,
  • Shivam Singh,
  • Tanvi Borse,
  • Kevin Kalinsky,
  • Anita Deswal,
  • Diego Sadler,
  • Vipul Chitalia,
  • Neal L. Weintraub,
  • Avirup Guha

摘要

Purpose of the Review

This review aims to examine the clinical relevance of cardio-kidney-metabolic syndrome (CKMS) in oncology, highlighting its role as both a preexisting comorbidity and a consequence of cancer treatment. It aims to integrating CKMS staging into personalized cancer care.

Recent Findings

CKMS is a progressive syndrome marked by dysfunction across cardiovascular, renal, and metabolic systems. Cancer therapies—particularly hormonal agents, immune checkpoint inhibitors, and chemotherapeutics—can accelerate or reveal underlying CKMS through inflammatory and metabolic pathways. Early risk stratification based on CKMS stage enables more effective monitoring, referral, and therapeutic strategies. A stage-based, multidisciplinary approach tailored to cancer type and comorbidity burden is essential for optimizing outcomes.

Summary

With rising multimorbidity among cancer patients, recognizing and addressing CKMS is increasingly critical. Routine CKMS assessment in oncology offers a pathway for earlier intervention and potentially altering its course. A comprehensive, individualized care model based on CKS stage is necessary to mitigate CKMS-related complications and deliver high-quality, integrated cancer care.